Chongqing Precision Biotech Co., Ltd

Quick facts

Phase 2 pipeline

• BCMA CAR-T cells · Oncology
  BCMA-targeting CAR-T cells
• pCAR-19B cells

Phase 1 pipeline

• Anti-CD123 CAR NK cells · Oncology
  CAR-T cell therapy targeting CD123
• Anti-CD19 UCAR-T cells
• Anti-CD5 CAR NK cells · Oncology
  Anti-CD5 CAR T cells target and kill cancer cells by binding to the CD5 receptor on their surface.
• BCMA targeted prime CAR-T cells
• C-4-29 Cells
• CD123 CAR-T cells
• CD123 targeted CAR-NK cells
• CD19 and CD22 targeted prime CAR- T cells
• CD19-targetd CAR-T
• CD19 targeted CAR-T cells
• CD70-targeted CAR-T cells
• CEA CAR-T cells
• Invivo CAR-T
• MC-1-50
• PTOC1
• Targeted CEA CAR-T

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chongqing Precision Biotech Co., Ltd portfolio CI brief
• Chongqing Precision Biotech Co., Ltd pipeline updates RSS